Citalopram hydrobromide combined with zolpidem

ApprovedSmall molecule

Citalopram hydrobromide combined with zolpidem is one of 37 small molecule programs targeting Insomnia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InsomniaActive, not recruiting

InsomniaApproved

Active, not recruiting

Competition

Competitive Landscape

153 competitors in Insomnia

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Phase 3

2 2

Elavil

AstraZeneca

Phase 3

1 3

Neurontin

VViatris Specialty LLC

Phase 3

7 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 5

Hetlioz

VVanda Pharmaceuticals

Phase 3

2 6

Gaboxadol

Lundbeck

Phase 3

8 7

Volinanserin

Sanofi

Phase 3

2 8

Citalopram hydrobromide combined with zolpidem

TTongji University

Approved

1 9

Prosom

AAbbott

Phase 3

4 10

Nitrazepam

Astellas

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Insomnia

NCT06740188

Clinical

Trials by Indication[1]

Insomnia1 trial

Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients

Recruiting·TTongji University·Phase 4·NCT06740188·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Citalopram hydrobromide combined with zolpidem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Citalopram hydrobromide combined with zolpidem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Citalopram hydrobromide combined with zolpidem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTongji University

Citalopram hydrobromide combined with zolpidem

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Insomnia1 trial

References

Drug Info

Quick Facts

Related News